Garland Jason K 4

What Happened
Jason K. Garland, Chief Financial Officer of REPLIGEN Corporation (RGEN), sold 733 shares on June 25, 2026 in an open-market transaction at $145.00 per share, generating proceeds of $106,285. This was a sale (not a purchase), which is often routine for executives managing their personal holdings.

Key Details

• Transaction date: June 25, 2026
• Filing date: June 26, 2026 (Form 4 accession 0001193125-26-285449) — filed the next day (timely).
• Transaction type/code: Sale (S), open-market or private sale reported as open-market.
• Price and proceeds: 733 shares × $145.00 = $106,285.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: Sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Garland on December 8, 2025 (pre-arranged plan).

Context
A 10b5-1 plan indicates the sale was pre-scheduled under a trading plan and is generally considered a routine way for insiders to sell shares without trading on nonpublic information. Such sales do not necessarily reflect a change in the executive’s view of the company.